1. Home
  2. INAB vs TVRD Comparison

INAB vs TVRD Comparison

Compare INAB & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.75

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

SELL

Current Price

$0.99

Market Cap

12.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
INAB
TVRD
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
12.6M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
INAB
TVRD
Price
$0.75
$0.99
Analyst Decision
Strong Buy
Buy
Analyst Count
3
9
Target Price
$7.00
★ $8.75
AVG Volume (30 Days)
69.2K
★ 184.7K
Earning Date
11-05-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 79.01
EPS
★ N/A
N/A
Revenue
N/A
★ $911,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 959.30
52 Week Low
$0.72
$0.77
52 Week High
$2.73
$5.69

Technical Indicators

Market Signals
Indicator
INAB
TVRD
Relative Strength Index (RSI) 32.88 43.90
Support Level N/A $0.85
Resistance Level $1.50 $1.09
Average True Range (ATR) 0.08 0.17
MACD -0.01 0.00
Stochastic Oscillator 9.62 20.86

Price Performance

Historical Comparison
INAB
TVRD

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: